Published in Hum Vaccin Immunother on May 01, 2012
Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother (2012) 1.00
New versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers. Indian J Med Res (2013) 0.96
Genome-Based Characterization of Emergent Invasive Neisseria meningitidis Serogroup Y Isolates in Sweden from 1995 to 2012. J Clin Microbiol (2015) 0.81
Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands. Int J Health Policy Manag (2015) 0.76
Nod1 detects a unique muropeptide from gram-negative bacterial peptidoglycan. Science (2003) 7.49
Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment. Lancet Infect Dis (2013) 2.95
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA (2008) 2.88
Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J Infect Dis (2002) 2.88
Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis (2007) 2.70
Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J Infect Dis (2009) 1.92
Clinical features and outcome of pediatric Neisseria meningitidis serogroup W135 infection: a report of 5 cases. Clin Infect Dis (2004) 1.69
The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005. Clin Infect Dis (2006) 1.66
From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak. Lancet Infect Dis (2011) 1.58
Down-regulation of pili and capsule of Neisseria meningitidis upon contact with epithelial cells is mediated by CrgA regulatory protein. Mol Microbiol (2002) 1.57
Recent increase in meningitis Caused by Neisseria meningitidis serogroups A and W135, Yaoundé, Cameroon. Emerg Infect Dis (2002) 1.42
The role of particular strains of Neisseria meningitidis in meningococcal arthritis, pericarditis, and pneumonia. Clin Infect Dis (2003) 1.41
Transgenic mice expressing human transferrin as a model for meningococcal infection. Infect Immun (2007) 1.28
Epidemiological changes in meningococcal meningitis in Niger from 2008 to 2011 and the impact of vaccination. BMC Infect Dis (2013) 1.27
Correlations between carbon metabolism and virulence in bacteria. Contrib Microbiol (2009) 1.25
Correlation between alterations of the penicillin-binding protein 2 and modifications of the peptidoglycan structure in Neisseria meningitidis with reduced susceptibility to penicillin G. J Biol Chem (2003) 1.25
Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One (2012) 1.23
Neisseria meningitidis strains isolated from invasive infections in France (1999-2002): phenotypes and antibiotic susceptibility patterns. Clin Infect Dis (2003) 1.23
Alterations of the pilQ gene in Neisseria gonorrhoeae are unlikely contributors to decreased susceptibility to ceftriaxone and cefixime in clinical gonococcal strains. J Antimicrob Chemother (2010) 1.20
The concept of "tailor-made", protein-based, outer membrane vesicle vaccines against meningococcal disease. Vaccine (2005) 1.17
A model of meningococcal bacteremia after respiratory superinfection in influenza A virus-infected mice. FEMS Microbiol Lett (2003) 1.17
Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? Vaccine (2012) 1.15
Detailed structural analysis of the peptidoglycan of the human pathogen Neisseria meningitidis. J Biol Chem (2003) 1.15
The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine (2011) 1.14
Biochemical and biological characteristics of cross-reacting material 197 CRM197, a non-toxic mutant of diphtheria toxin: use as a conjugation protein in vaccines and other potential clinical applications. Biologicals (2011) 1.10
Interlaboratory comparison of agar dilution and Etest methods for determining the MICs of antibiotics used in management of Neisseria meningitidis infections. Antimicrob Agents Chemother (2003) 1.10
Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines. Clin Vaccine Immunol (2012) 1.06
A novel metal transporter mediating manganese export (MntX) regulates the Mn to Fe intracellular ratio and Neisseria meningitidis virulence. PLoS Pathog (2011) 1.04
Conserved virulence of C to B capsule switched Neisseria meningitidis clinical isolates belonging to ET-37/ST-11 clonal complex. Microbes Infect (2005) 1.03
The establishment of Neisseria meningitidis serogroup W135 of the clonal complex ET-37/ST-11 as an epidemic clone and the persistence of serogroup A isolates in Burkina Faso. Microbes Infect (2005) 1.02
Transcription regulators potentially controlled by HPr kinase/phosphorylase in Gram-negative bacteria. J Mol Microbiol Biotechnol (2003) 1.01
Meningococcal serogroup Y emergence in Europe: update 2011. Hum Vaccin Immunother (2012) 1.00
Influenza A virus neuraminidase enhances meningococcal adhesion to epithelial cells through interaction with sialic acid-containing meningococcal capsules. Infect Immun (2009) 0.99
Experimental meningococcal sepsis in congenic transgenic mice expressing human transferrin. PLoS One (2011) 0.98
Ciprofloxacin resistance in Neisseria meningitidis, France. Emerg Infect Dis (2008) 0.97
Standardized nonculture techniques recommended for European reference laboratories. FEMS Microbiol Rev (2006) 0.97
Serum visfatin concentrations are positively correlated with serum triacylglycerols and down-regulated by overfeeding in healthy young men. Am J Clin Nutr (2007) 0.97
Direct and rapid identification and genogrouping of meningococci and porA amplification by LightCycler PCR. J Clin Microbiol (2002) 0.97
The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2. Blood (2013) 0.97
Glycoconjugate vaccines: an update. Expert Opin Biol Ther (2014) 0.96
Differential modulation of TNF-alpha-induced apoptosis by Neisseria meningitidis. PLoS Pathog (2009) 0.96
Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines (2011) 0.95
Emergence of new virulent Neisseria meningitidis serogroup C sequence type 11 isolates in France. J Infect Dis (2010) 0.95
Staphylococcus epidermidis surface protein I (SesI): a marker of the invasive capacity of S. epidermidis? J Med Microbiol (2009) 0.95
Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J Clin Pharmacol (2003) 0.94
Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults. Hum Vaccin (2011) 0.94
Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine. BMC Microbiol (2014) 0.93
Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review. Microbiology (2011) 0.93
Impact of MenBvac, an outer membrane vesicle (OMV) vaccine, on the meningococcal carriage. Vaccine (2013) 0.91
Changes in the transcriptome of abdominal subcutaneous adipose tissue in response to short-term overfeeding in lean and obese men. Am J Clin Nutr (2008) 0.91
Immunogenicity of meningococcal PBP2 during natural infection and protective activity of anti-PBP2 antibodies against meningococcal bacteraemia in mice. J Antimicrob Chemother (2006) 0.89
Analysis in vitro and in vivo of the transcriptional regulator CrgA of Neisseria meningitidis upon contact with target cells. Mol Microbiol (2004) 0.89
A multi-country evaluation of Neisseria meningitidis serogroup B factor H-binding proteins and implications for vaccine coverage in different age groups. Pediatr Infect Dis J (2013) 0.89
Rifampin-resistant Neisseria meningitidis. Emerg Infect Dis (2006) 0.88
Association of meningococcal phenotypes and genotypes with clinical characteristics and mortality of meningitis in children. Pediatr Infect Dis J (2010) 0.88
Concordance of BAI and BMI with DXA in the Newfoundland population. Obesity (Silver Spring) (2013) 0.87
Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013. Hum Vaccin Immunother (2015) 0.87
The Neisseria meningitidis adhesion regulatory protein CrgA acts through oligomerization and interaction with RNA polymerase. Mol Microbiol (2003) 0.87
Novel meningococcal 4CMenB vaccine antigens - prevalence and polymorphisms of the encoding genes in Neisseria gonorrhoeae. APMIS (2012) 0.86
Draft Genome Sequence of a Neisseria meningitidis Serogroup C Isolate of Sequence Type 11 Linked to an Outbreak among Men Who Have Sex with Men. Genome Announc (2013) 0.86
Mobile microbiological laboratory support for evaluation of a meningitis epidemic in Northern Benin. PLoS One (2013) 0.85
The use of vaccine antigen characterization, for example by MATS, to guide the introduction of meningococcus B vaccines. Vaccine (2012) 0.85
Functional impacts of the diversity of the meningococcal factor H binding protein. Vaccine (2012) 0.85
Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks. Vaccine (2006) 0.85
Differential expression of genes that harbor a common regulatory element in Neisseria meningitidis upon contact with target cells. Infect Immun (2003) 0.85
Penicillin resistance compromises Nod1-dependent proinflammatory activity and virulence fitness of neisseria meningitidis. Cell Host Microbe (2013) 0.84
De-O-acetylation of peptidoglycan regulates glycan chain extension and affects in vivo survival of Neisseria meningitidis. Mol Microbiol (2013) 0.84
The script concordance test as a measure of clinical reasoning: a national validation study. Am J Surg (2012) 0.83
The challenge of post-implementation surveillance for novel meningococcal vaccines. Vaccine (2012) 0.82
Differential role of lipooligosaccharide of Neisseria meningitidis in virulence and inflammatory response during respiratory infection in mice. Infect Immun (2006) 0.82
Enteroviral meningitis does not exclude concurrent bacterial meningitis. J Clin Microbiol (2011) 0.82
Evolution of immune response against Neisseria meningitidis B:14:P1.7,16 before and after the outer membrane vesicle vaccine MenBvac. Vaccine (2012) 0.81
Target gene sequencing to define the susceptibility of Neisseria meningitidis to ciprofloxacin. Antimicrob Agents Chemother (2013) 0.80
Neisseria meningitidis pili induce type-IIA phospholipase A2 expression in alveolar macrophages. FEBS Lett (2005) 0.80
Chronic meningococcemia cutaneous lesions involve meningococcal perivascular invasion through the remodeling of endothelial barriers. Clin Infect Dis (2012) 0.79
Whole-Genome Characterization of Epidemic Neisseria meningitidis Serogroup C and Resurgence of Serogroup W, Niger, 2015. Emerg Infect Dis (2016) 0.79
Adequacy of pediatric triage. Disaster Med Public Health Prep (2012) 0.78
Decreased susceptibility to chlorhexidine and prevalence of disinfectant resistance genes among clinical isolates of Staphylococcus epidermidis. APMIS (2014) 0.78
Transport and Catabolism of Carbohydrates by Neisseria meningitidis. J Mol Microbiol Biotechnol (2016) 0.77
Laboratory evaluation of a rapid diagnostic test for Neisseria meningitidis serogroup A. Trans R Soc Trop Med Hyg (2013) 0.77
Immunisation against meningococcus B. Lancet (2013) 0.77
Penicillin binding proteins as danger signals: meningococcal penicillin binding protein 2 activates dendritic cells through Toll-like receptor 4. PLoS One (2011) 0.77
Gene variability and degree of expression of vaccine candidate factor H binding protein in clinical isolates of Neisseria meningitidis. APMIS (2012) 0.77
Occurrence of nodular lymphocyte-predominant hodgkin lymphoma in hermansky-pudlak type 2 syndrome is associated to natural killer and natural killer T cell defects. PLoS One (2013) 0.77
Invasive serogroup w meningococcal disease in children: a national survey from 2001 to 2008 in France. Pediatr Infect Dis J (2013) 0.76
Neisseria meningitidis Serogroup X in Sub-Saharan Africa. Emerg Infect Dis (2016) 0.76
Late repression of NF-κB activity by invasive but not non-invasive meningococcal isolates is required to display apoptosis of epithelial cells. PLoS Pathog (2011) 0.76
Vaccine Failure After Meningococcal C Conjugate Vaccine May Be Linked to Decline of Bactericidal Titers and Absence of Herd Immunity. Pediatr Infect Dis J (2015) 0.75
Travel-related Neisseria meningitidis serogroup W135 infection, France. Emerg Infect Dis (2013) 0.75
Corticosteroids for bacterial meningitis. N Engl J Med (2008) 0.75
Evaluation of molecular typing methods for identification of outbreak-associated Neisseria meningitidis isolates. APMIS (2012) 0.75
Proficiency of PCR in hospital settings for nonculture diagnosis of invasive meningococcal infections. Clin Lab (2012) 0.75
Neonatal Meningococcal Meningitis In France From 2001 To 2013. Pediatr Infect Dis J (2016) 0.75
[Meningococcal vaccines: present status and perspectives]. Therapie (2005) 0.75
[Meningococcal disease due to Neisseria meningitidis serogroup W135 in children. Clinical aspects and outcome]. Presse Med (2004) 0.75